FDA Review Resumes for Off-the-Shelf Cell Therapy Aimed at a Rare, Often-Fatal Transplant Complication

What This Article Covers

On September 30, 2026, Pierre Fabre Pharmaceuticals and its partner Atara Biotherapeutics announced they had resubmitted a Biologics License Application (BLA) to the FDA for tabelecleucel (tab-cel), an off-the-shelf, donor-derived T-cell immunotherapy for Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) — a rare cancer-like complication that can arise after a stem cell or organ transplant and, once it stops responding to first-line treatment, has few good options. The therapy is already approved in Europe. This article covers what the resubmission contains, why the FDA twice declined to approve it in the U.S., and what the newly strengthened data actually show — while being clear that, as of this writing, tab-cel is still not an approved treatment in the United States.

What Happened

Tabelecleucel is an allogeneic "off-the-shelf" EBV-specific cytotoxic T-cell therapy — meaning it's manufactured in advance from healthy donor cells and kept in inventory, ready to infuse, rather than custom-made for each patient the way autologous CAR-T products are. It's already sold in Europe under the brand name Ebvallo, where the European Commission approved it in December 2022 as the first-ever authorized therapy for EBV+ PTLD.

In the U.S., the path has been rockier. The FDA issued a first complete response letter (CRL) in January 2025, but that one cited manufacturing issues at a third-party facility — not concerns about the drug's safety or effectiveness. A second CRL followed in January 2026, this time questioning whether the pivotal trial, a single-arm Phase 3 study called ALLELE (NCT03394365), provided strong enough evidence to support accelerated approval. After a "productive" Type A meeting with the FDA in April 2026, the companies were told they could resubmit using the existing ALLELE trial — but with a beefed-up data package. That resubmission landed September 30, 2026, adding more patients and longer follow-up from ALLELE, plus supporting data from an expanded access program, a separate clinical study, and real-world commercial experience gathered in Europe since 2022.

What the Data Actually Show

EBV+ PTLD develops when donor or recipient Epstein-Barr virus-infected B cells proliferate unchecked because a transplant patient's immune system has been suppressed to prevent organ rejection or graft-versus-host disease. First-line treatment is typically rituximab, often combined with reduced immunosuppression and sometimes chemotherapy — but no PTLD-specific therapy is currently FDA-approved for patients whose disease progresses after that.

This is the population tab-cel targets, and the numbers are genuinely encouraging without being a slam dunk. Across the ALLELE data reported at the American Society of Hematology's 2024 meeting, the overall objective response rate (ORR) was 50.7% (95% CI, 38.9%-62.4%), with similar results in patients who'd had a solid organ transplant (ORR 51.0%) and those who'd had a hematopoietic cell transplant (ORR 50.0%). About 28% of patients achieved a complete response, and among those who responded, the median duration of response was roughly 23 months — a meaningfully durable remission in a population that, by definition, had already failed standard therapy. Median overall survival in the dataset was reported at 18.4 months.

On safety, no cases of cytokine release syndrome, infusion reactions, or graft-versus-host disease were reported in the trials — a real point in tab-cel's favor given that CRS and GvHD are the signature risks of many cell and gene therapies. That said, serious treatment-emergent adverse events occurred in a substantial share of patients: 65.4% in the HCT cohort and 61.2% in the SOT cohort. This is a sick, heavily pretreated patient population, so some of that burden likely reflects the underlying disease and prior treatments rather than the cell therapy itself — but it's a real caveat, not a footnote to skip past.

Why the FDA Said No, Twice — and Why That Matters

It's worth being precise about what each rejection actually meant. The 2025 CRL was a manufacturing problem at a third-party facility, unrelated to whether the drug works — the kind of issue that, once fixed, doesn't reflect on the therapy's clinical merit. The 2026 CRL was more substantive: regulators weren't convinced that a single-arm trial, without a randomized comparator, cleared the bar for "substantial evidence of effectiveness" under the accelerated approval pathway. That's a legitimate scientific concern, not FDA foot-dragging, and it's the reason this resubmission leans on a larger, longer-followed ALLELE dataset plus independent supporting evidence — essentially, more data points aimed directly at the question the agency raised.

No PDUFA (target decision) date has been set yet. Atara's leadership has said only that it will share an updated timeline once one exists, and that the company continues to support Pierre Fabre — which holds the BLA and controls the submission — as it prepares for FDA's review.

What This Means for Patients Right Now

For patients and families facing EBV+ PTLD today, the honest takeaway is: tabelecleucel is not an approved option in the United States, and there's no guarantee or confirmed timeline for when — or whether — that will change. It is approved and in clinical use in Europe, and the accumulating real-world experience there is part of what's being submitted to U.S. regulators. The condition itself is serious enough that Atara's own CEO has pointed out that patients are still dying from EBV-driven PTLD while no PTLD-specific therapy is available stateside — which is precisely the gap this resubmission is aimed at closing, assuming the data holds up to FDA scrutiny this time.

Bottom Line

This is a genuinely hopeful development, but a measured one: an already-approved European cell therapy, built from a scientifically elegant "off-the-shelf" donor T-cell platform, is getting a third serious look from U.S. regulators after addressing their specific prior objection with a larger, more mature dataset. A roughly 50% response rate with durable remissions in previously treatment-refractory patients is meaningful progress for a rare and dangerous complication with few alternatives — but it's a response rate, not a cure, and the therapy remains unapproved in the U.S. with no confirmed decision date. Patients and clinicians should watch for FDA's response to this resubmission rather than treating approval as a foregone conclusion.